Phleomycin D1

O=C(C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C)N[C@H](C(N[C@H](C)[C@@H](O)[C@H](C)C(N[C@]([C@H](O)C)([H])C(NCCC2=N[C@@H](C3=NC(C(NCCCCNC(N)=N)=O)=CS3)CS2)=O)=O)=O)[C@H](C4=CN=CN4)O[C@H]5[C@H]([C@H]([C@@H]([C@@H](O5)CO)O)O)O[C@]6([H])[C@H]([C@H]([C@@H]([C@H](O6)CO)O)OC(N)=O)O

[1]Ishizuka M, et, al. Studies on antitumor activity, antimicrobial activity and toxicity of phleomycin. J Antibiot (Tokyo) . 1966 Nov;19 (6) :260-71.|[2]Huang CH, et, al. Bifunctional intercalation of antitumor antibiotics BBM-928A and echinomycin with deoxyribonucleic acid. Effects of intercalation on deoxyribonucleic acid degradative activity of bleomycin and phleomycin. Biochemistry. 1982 Jul 20;21 (15) :3704-10. |[3]Robles SJ, et al. Permanent cell cycle arrest in asynchronously proliferating normal human fibroblasts treated with doxorubicin or etoposide but not camptothecin. Biochem Pharmacol. 1999 Aug 15;58 (4) :675-85.